Human Pathology
Volume 41, Issue 5 , Pages 686-696 , May 2010

Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance

  • Zhong-Sheng Zhao, PhD

      Affiliations

    • Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China
    • Corresponding Author InformationCorresponding author.
    • ,
  • Yong-Quan Chu, BSc

      Affiliations

    • Department of Oncosurgery, The First Hospital of Jiaxing, Jiaxing 314000, China
    • ,
  • Zai-Yuan Ye, MD

      Affiliations

    • Department of Gastroenterology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China
    • ,
  • Yuan-Yu Wang, MD

      Affiliations

    • Department of Gastroenterology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China
    • ,
  • Hou-Quan Tao, MD

      Affiliations

    • Department of Gastroenterology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China

Received 9 July 2009 ,Revised 9 October 2009 ,Accepted 15 October 2009.

References 

  1. Wang CS, Chao TC, Jan YY, et al. Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J. 2002;25:792–802
  2. Choi SR, Jang JS, Lee JH, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci. 2006;51:2081–2086
  3. Shim KN, Jung SA, Joo YH, Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007;42:120–128
  4. Motrescu ER, Rio MC. Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem. 2008;389:1037–1041
  5. Deng H, Guo RF, Li WM, et al. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun. 2005;326:274–281
  6. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990;348:699–704
  7. Kren L, Goncharuk VN, Krenova Z, et al. Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol. 2006;42:16–19
  8. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003;23:3937–3944
  9. Wasenius VM, Hemmer S, Kettunen E, et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 2003;9:68–75
  10. Mellick AS, Blackmore D, Weinstein SR, Griffiths LR. An assessment of MMP and TIMP gene expression in cell lines and stroma—tumour differences in microdissected breast cancer biopsies. Tumour Biol. 2003;24:258–270
  11. Pedersen G, Saermark T, Kirkegaard T, Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol. 2009;155:257–265
  12. Hegedus L, Cho H, Xie X, Eliceiri GL. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol. 2008;216:480–485
  13. Wlodarczyk J, Stolte M, Mueller J. E-cadherin, beta-catenin and stromelysin-3 expression in de novo carcinoma of the colorectum. Pol J Pathol. 2001;52:119–124
  14. Mueller J, Steiner C, Hofler H. Stromelysin-3 expression in noninvasive and invasive neoplasms of the urinary bladder. Hum Pathol. 2000;31:860–865
  15. Mueller J, Brebeck B, Schmalfeldt B, et al. Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential. Virchows Arch. 2000;437:618–624
  16. Franciosi CM, Piacentini MG, et al. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study. Hepatogastroenterology. 2003;50:297–300
  17. Chen PP, Li WJ, Wang Y, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE. 2007;2:e534
  18. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003;200:39–46
  19. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001;92:1427–1434
  20. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol. 2003;16:79–84
  21. Kolev Y, Uetake H, Iida S, et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 2007;14:2738–2747
  22. Song LB, Liao WT, Mai HQ, et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett. 2006;242:258–265
  23. Fiorentino M, Fu L, Shi YB. Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency. Int J Mol Med. 2009;23:389–397
  24. Motrescu ER, Blaise S, Etique N, et al. Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene. 2008;27:6347–6355
  25. Perigny M, Bairati I, Harvey I, et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol. 2008;129:226–231
  26. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252–257
  27. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004;67:300–309
  28. Massi D, Franchi A, Ketabchi S, et al. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol. 2003;34:80–88
  29. Kasper G, Reule M, Tschirschmann M, et al. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway. BMC Cancer. 2007;7:12
  30. Ito Y, Yoshida H, Kakudo K, et al. Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology. 2006;38:421–425
  31. Noel A, Boulay A, Kebers F, et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene. 2000;19:1605–1612
  32. Nedic O, Malenkovic V, Nikolic JA, Baricevic I. Insulin-like growth factor I (IGF-I) as a sensitive biomarker of catabolism in patients with gastrointestinal diseases. J Clin Lab Anal. 2007;21:335–339
  33. Pham TM, Fujino Y, Kikuchi S, et al. A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3. Eur J Cancer. 2007;43:1611–1616
  34. Jiang Y, Wang L, Gong W, et al. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004;21:755–764

 This study was supported by the Zhejiang Provincial Department of Science and Technology Research Foundation (2008C33040) and the Zhejiang Provincial Medical Science Research Foundation (2007A013).

PII: S0046-8177(09)00375-X

doi: 10.1016/j.humpath.2009.10.010

Human Pathology
Volume 41, Issue 5 , Pages 686-696 , May 2010

Article Tools

* Image Usage & Resolution